Katherine Goodrich - 15 Dec 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Dec 2025
Net transactions value
$0
Form type
4
Filing time
14 Jan 2026, 19:32:41 UTC
Previous filing
16 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Goodrich Katherine Director C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Scott Sieckert, Attorney-in-Fact 14 Jan 2026 0002044770

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +2,233 2,233 15 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -2,233 -33% $0.000000 4,467 15 Dec 2025 Common Stock 2,233 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 Each RSU represents a contingent right to receive one share of the Company's common stock.
F3 The RSUs will vest in three equal installments on December 15th of 2025, 2026 and 2027, subject to the Reporting Person's continuous service.